Ten-year experience of selective omission of the pretransplant crossmatch test in deceased donor kidney transplantation

Transplantation

Volumn 89, Issue 2, 2010, Pages 185-193

  Taylor, Craig J ^a   Kosmoliaptsis, Vasilis ^a,b   Sharples, Linda D ^c   Prezzi, Davide ^a,b   Morgan, C Helen ^a   Key, Timothy ^a   Chaudhry, Afzal N ^a   Amin, Irum ^b   Clatworthy, Menna R ^a   Butler, Andrew J ^b   Watson, Christopher J E ^b   Bradley, J Andrew ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cold ischemia time; Crossmatching; Deceased donor; Kidney transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; HLA ANTIBODY; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY SCREENING; ARTICLE; BRAIN DEATH; COLD ISCHEMIA; CONTROLLED STUDY; DELAYED GRAFT FUNCTION; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART DEATH; HUMAN; KIDNEY DONOR; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SAFETY; SENSITIZATION; TREATMENT OUTCOME;

ADULT; AGED; BRAIN DEATH; CADAVER; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TISSUE DONORS;

EID: 76649101082     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181c926f2     Document Type: Article

References (40)

1. Kissmeyer-Nielsen F, Olsen S, Petersen VP, et al. Hyperacute rejection of kidney allografts associates with pre-existing humoral antibodies against donor cells. Lancet 1966; 1: 662.
2. Williams GM, Hume DM, Hudson RP Jr, et al. "Hyperacute" renal-homograft rejection in man. N Engl J Med 1968; 279: 611.
3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280: 735.
4. Fuggle SV, Taylor CJ. Histocompatibility in renal transplantation. In: Morris PJ, Knechtle SJ, eds. Kidney transplantation, principles and practices, [ed. 6]. Philadelphia USA, Pub. Saunders Elsevier 2008, pp 140.
5. Garovoy MR, Rheinschmilt MA, Bigos M, et al. Flow cytometric analysis: A high technology crossmatch technique facilitating transplantation. Trans Proc 1983; 15: 1939.
6. Mahoney RJ, Norman DJ, Colombe BW, et al. Identification of high-and low-risk second kidney grafts. Transplantation 1996; 61: 1349.
7. Quiroga I, McShane P, Koo DD, et al. Major effects of delayed graft function and cold ischaemia time on renal allograft survival. Nephrol Dial Transplant 2006; 21: 1689.
8. Mikhalski D, Wissing KM, Ghisdal L, et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. Transplantation 2008; 85(7 suppl): S3.
9. Takemoto SK, Terasaki PI, Gjertson DW, et al. Twelve years' experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343: 1078.
10. Kaneku HK, Terasaki PI. Thirty year trend in kidney transplants: UCLA and UNOS Renal Transplant Registry. Clin Transpl 2006: 1.
11. Doxiadis II, Smits JM, Persijn GG, et al.It takes six toboogie: Allocating cadaver kidneys in Eurotransplant. Transplantation 2004; 77: 615.
12. Pei R, Lee J-H, Shih N-J, et al. Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 2003; 75: 43.
13. Claas FH, Witvliet MD, Duquesnoy RJ, et al. The acceptable mismatch program as a fast tool to transplant highly sensitized patients awaiting a post-mortal kidney: Short waiting time and excellent graft outcome. Transplantation 2004; 78: 190.
14. Bray RA, Nolen JD, Larsen C, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant 2006; 6: 2307.
15. Matas AJ, Sutherland ER. Kidney transplantation without a final cross-match. Transplantation 1998; 66: 1835.
16. Dyer PA, Taylor CJ. Renal transplantation without a pre-transplant crossmatch. Transplantation 2000; 69: 460.
17. Taylor CJ, Chapman JR, Ting A, et al. Characterisation of lymphocy-totoxic antibodies causing a positive crossmatch in renal transplantation: Relationship to primary and regraft outcome. Transplantation 1989; 48: 953.
18. Harmer A, Dyer PJ; on behalf of the British Society for Histocompatibility and Immunogenetics and British Transplantation Society. Guidelines for the detection and characterisation of clinically relevant antibodies in solid organ transplantation. ISBN: 0-9542221-6-4. Available at www.bts. org.uk/transplantation/standards-and-guidelines; 2004.
19. Taylor CJ, Smith SI, Morgan CH, et al. Selective omission of the donor crossmatch before renal transplantation: Efficacy, safety and effects on cold storage time. Transplantation 2000; 69: 719.
20. Robson A, Martin S. T and B cell crossmatching using three-colour flow cytometry. Trans Immunol 1996; 4: 203.
21. Taylor CJ, Kosmoliaptsis V, Summers DM, et al. Back to the future: application of contemporary technology to long-standing questions about the clinical relevance of human leukocyte antigen-specific al-loantibodies in renal transplantation. Hum Immunol 2009; 70: 563
22. Morris PJ, Johnson RJ, Fuggle SV, et al. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. Lancet 1999; 354: 1147.
23. Rudge C, Johnson RJ, Fuggle SV, et al; Kidney and Pancreas Advisory Group, UK Transplant NHS BT. Renal transplantation in the United Kingdom for patients from ethnic minorities. Transplantation 2007; 83: 1169.
24. Kerman RH, Susskind B, Buyse I, et al. Flow cytometry-detected IgG is not a contraindication to renal transplantation: IgM may be beneficial to outcome. Transplantation 1999; 68: 1855.
25. Nikaein A, Cherikh W, Nelson K, et al. Organ procurement and transplantation network/united network for organ sharing histocompatibil-ity committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87: 557.
26. Appel JZ, Hartwig MG, Cantu E, et al. Role of flow cytometry to define unacceptable HLA antigens in lung transplant recipients with HLA-specific antibodies. Transplantation 2006; 81: 1049.
27. Vacher-Coponat H, Purgus R, Indreies M, et al. Cold ischemia time in renal transplantation is reduced by a timesheet in a French transplant center. Transplantation 2007; 83: 561.
28. Ojo AO, Wolfe RA, Held PJ, et al. Delayed graft function: Risk factors and implications for renal allograft survival. Transplantation 1997; 63: 968.
29. Salahudeen AK, Haider N, May W. Cold ischemia and the reduced long-term survival of cadaveric renal allografts. Kidney Int 2004; 65: 713.
30. Opelz G, Döhler B. Multicenter analysis of kidney preservation. Transplantation 2007; 83: 247.
31. Hernández D, Estupiñán S, Pérez G, et al. Impact of cold ischemia time on renal allograft outcome using kidneys from young donors. Transpl Int 2008; 21: 955.
32. Gjertson DW. Impact of delayed graft function and acute rejection on kidney graft survival. In: Cecka JM, Terasaki PI, eds. Clinical transplants 2000. Los Angeles, CA: Tissue Typing Laboratory 2001, pp 467.
33. Taylor CJ, Welsh KI, Gray CM, et al. Clinical and socio-economic benefits of serological HLA-DR matching for renal transplantation over three erasofimmunosuppression regimensinasingle unit. In: Terasaki PI, Cecka JM, eds. Clinical transplants 1993. Los Angeles, CA: UCLA Tissue Typing Laboratory 1994, pp 233.
34. Opelz G, Döhler B. Effect of human leukocyte antigen compatibility on kidney graft survival: Comparative analysis of two decades. Transplantation 2007; 84: 137.
35. Heinze G, Oberbauer R, Kainz A, et al. Calcineurin inhibitor-based immunosuppressive therapy, donor age, and long-term outcome after kidney transplantation. Transplantation 2009; 87: 1821.
36. Port FK, Bragg-Gresham JL, Metzger RA, et al. Donor characteristics associated with reduced graft survival: An approach to expanding the pool of kidney donors. Transplantation 2002; 74: 1281.
37. Collins MG, Chang SH, Russ GR, et al. Outcomes of transplantation using kidneys from donors meeting expanded criteria in Australia and New Zealand, 1991 to 2005. Transplantation 2009; 87: 1201.
38. McLaren AJ, Jassem W, Gray DW, et al. Delayed graft function: Risk factors and the relative effects of early function and acute rejection on long-term survival in cadaveric renal transplantation. Clin Transplant 1999; 13: 266.
39. Jackson AM, Zachary AA. The problem of transplanting the sensitized patient: Whose problem is it? Front Biosci 2008; 13: 1396.
40. Magee JC, Barr ML, Basadonna GP, et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant 2007; 7(5 Pt 2): 1424.